证券日报网讯 1月20日，华特达因在互动平台回答投资者提问时表示，公司聚焦主业，以儿童临床需求 和营养健康需要为导向，着力构建两大类系统化产品矩阵，一是在"伊可新"基础上进行品类延伸，形成 包含营养、呼吸、消化、精神等领域的儿童用药产品矩阵，二是以"伊可新"品牌延伸，形成涵盖基础营 养、眼脑发育、肠道健康、免疫健康、皮肤护理五大领域的儿童大健康产品矩阵，未来公司将继续进一 步丰富儿童药品和健康产品矩阵，通过多元化产品满足不同年龄段青少年多元化的营养健康需求，不断 巩固和发展公司核心竞争能力和经营业绩。 （编辑 楚丽君） ...

Group 1 - The core viewpoint of the news is that Kangzhi Pharmaceutical has seen a significant increase in its stock price, rising by 5.14% to 7.57 CNY per share, with a trading volume of 427 million CNY and a turnover rate of 13.03%, leading to a total market capitalization of 3.445 billion CNY [1] - Kangzhi Pharmaceutical, established on January 20, 1994, and listed on May 26, 2010, is a leading domestic children's health enterprise in China, focusing on the research, production, and sales of children's medicine, maternal and infant health products, and medical protective equipment [1] - The company's main business revenue composition includes 76.16% from children's medicine, 20.89% from adult medicine, and 2.94% from other supplementary products [1] Group 2 - Among the top ten circulating shareholders of Kangzhi Pharmaceutical, a fund under Nuoan Fund, specifically Nuoan Multi-Strategy Mixed A (320016), has entered the top ten in the second quarter, holding 1.9087 million shares, which accounts for 0.43% of the circulating shares [2] - The Nuoan Multi-Strategy Mixed A fund has achieved a year-to-date return of 62.9%, ranking 344 out of 8161 in its category, and an annual return of 88.6%, ranking 126 out of 8021 [2] - The fund has been in existence since August 9, 2011, with a total size of 1.399 billion CNY and a cumulative return of 214.4% since its inception [2]